Normal Granulopoiesis and Its Alterations in Murine Myelogenous Leukemia by Graham, James D.
NORMAL CxRANULOPOIESIS AND ITS ALTERATIONS IN
MURINE MYELOGENOUS LEUKEMIA1
JAMES D. GRAHAM, P H . D .
Leukemia Research Laboratory, Department of Biology, Bowling Green State University,
Bowling Green, Ohio 43403
ABSTRACT
This paper presents a review of the current knowledge of the process of granulopoiesis,
and the kinetics and control of the process. The author makes a case for the understanding
of normal developmental mechanisms and their control as a basis to the study of
malignancy.
Stimulatory factors regulating the processes of proliferation, maturation, and release
of mature granulocytes from the marrow are described. Inhibitory factors, such as chalone
and the intermediate-molecular-weight protein "X" are also related to the overall control
mechanism.
Application of control factors and antiserum to the stimulatory factors in the therapy
in murine myelogenous leukemia has produced interesting results. An antiserum to the
proliferation-stimulating factor, given prophylactically, produces prolonged survival and
maintains "normal" hematologic values. Both the macroglobulin maturation factor and
antiserum to it are effective in therapeutic regimens, prolonging survival and "normal"
hematologic values. Finally, the inhibitor "X" has produced extended survival in thera-
peutic use.
These results suggest that the leukemic state is due to an alteration in the normal con-
trol mechanism and not to a permanent alteration of the cells. If these findings are born
out in further studies, myelogenous leukemia stands in direct contrast to most forms of
neoplasia, where cells are permanently transformed. Other laboratories have already
suggested that this is the case for human myelogenous leukemia.
INTRODUCTION
The exciting evidences presented for the implication of a C-type RNA virus
in murine and human leukemia have produced striking changes in the broad pattern
of leukemia research. The past several years, have seen the discovery of reverse
transcriptases (RNA-dependent DNA polymerases), and of the presence of these
enzymes in human leukemic cells and in virus-like particles isolated from human
milk (Temin and Mizutani, 1970; Baltimore, 1970; Gallo, et al., 1970; Schlom,
et al., 1971). Virus-specific antigens have been described which can be used to
identify suspected leukemia viruses and which lead to a dream of "cancer vac-
cines." Only a short time ago, this degree of progress was undreamed of.
Every burst of optimism, however, must be tempered by the cold facts of a
realistic world. The discovery of specific inhibitors for the viral reverse tran-
scriptases was tempered by the reality that this was not a "magic bullet" that
would strike down cancer viruses wherever they occurred, but rather might be
effective at certain points in the course of the disease. The discovery of virus
antigens and the possibility of a vaccine has been tempered by the "oncogene
hypothesis," or the alternative "provirus concept," and its supporting evidence,
which suggest that the viral nucleic acid is transcribed to DNA and the viral
genome becomes incorporated into the chromosomes of the host cell, thus being
protected against attack.
Unless a "magic bullet" drug or a cancer vaccine is produced in the immediate
future, a more basic approach must be considered. Because leukemia in particular
and neoplasia in general involve alterations in proliferation and differentiation of
cells, a full and clear understanding of normal developmental processes and the
control of these events is basic to a "cure" or to prevention of the disease. Sec-
ondly, if the changes in the developmental process resulting in myelogenous
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leukemia are discovered, a series of opportunities for therapeutic management of
the disease are presented. Thirdly, if a clear picture of the disease process in
leukemia is obtained, much light will be shed on other forms of cancer, whether
they are varying manifestations of a single disease or discrete entities. All are
related in their alterations of the growth and developmental process, and in the
fact that increased knowledge of development must hasten the time when errors
in the process may be corrected or avoided.
For these reasons, our laboratory has begun to apply the limited but increasing
knowledge of factors controlling the development of granulocytic leukocyte
(granulopoiesis) to the study of possible alterations in this control mechanism in
murine myelogenous leukemia. Whether a particular malignancy is virus-in-
duced or a result of genetic or environmental changes, we feel that it is now pos-
sible to learn what changes are produced in the developmental process by these
carcinogens.
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FIGURE 1. Top—Leukemia virus permanently altering host cells. Middle—Leukemia virus
renders cell unstable and more sensitive to imbalances of control factors. Bottom
—Leukemia virus does not affect cell but causes imbalance of control factors.
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In studying an altered developmental process, two types of changes must be
considered. First, the undiflerentiated (primitive, embryonic, stem) cell which
gives rise to the mature fully differentiated granulocyte may itself be altered (fig.
1A). Thus, whether the control mechanism functions properly or not, the cell
can not follow the normal differentiation process and reach maturity. Secondly,
the undifferentiated cell may be completely normal, but be unable to reach
maturity because of damaged or changed control process (fig. IB and 1C). With-
out the proper external stimuli, the cell would be partially or totally unable to
become a fully differentiated granulocyte.
Before discussing the hypothesis that myelogenous leukemis is a manifestation
of an altered control mechanism for the process of a granulocyte development, a
clear understanding of normal granulopoiesis must be present. This is especially
true because the literature in the field is cluttered with several sets of svnonomous
nomenclature. This already-complicated procedure has been rendered thoroughly
befuddled by an unstandardized vocabulary and irreproducible experimentation.
Therefore, it seems useful to set down a brief synthesis of what is known and what
remains unknown about the process of granulocyte development, and its kinetics
and regulation.
PATHWAYS OF MYELOPOIESIS
In the early days of experimental hematology, there existed as many theories
for the developmental origin of the different blood cells as there were laboratories.
One extreme was the polyphyletic school, with a belief that erythrocytes, granu-
locytes, lymphocytes, monocytes, and perhaps megakaryocytes came from indi-
vidual ancestral, or "stem," cells, with no relation between groups except in the
embryo (Doan, 1932; Sabin, et al., 1936). The other was the monophyletic belief
that a common "stem" cell was the forerunner of all the different mature blood
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cells (Maximow, 1924; Jordon, 1935; Bloom, 1940). The common parent cell
was usually referred to as a pleuripotential stem cell, because it could differentiate
into several kinds of mature forms. If these were the "black" and the "white"
among theories describing hemopoiesis, there were many more which were shades
of gray.
More recently, a unified concept has emerged, with a single alternate version.
Elegant experiments designed to study the repopulation of bone marrow in ir-
radiated animals have shown that implanted hematopoietic tissue will proliferate
and form macroscopic colonies in the spleen of the irradiated recipient (Till and
McCulloch, 1961). These colonies were derived from a single cell and contained
myeloid, erythroid, and lymphoid elements (Becker, McCulloch, and Till, 19(53).
Tests of steroid hormone (testosterone) and stress effects on blood-cell production
have provided strong evidence that erythroid elements and granulocytic leuko-
cytes share a common origin. For example, testosterone treatment stimulates
erythrocyte production in experimental animals, and at the same time, a decrease
in granulopoiesis is evident. Erythropoietin, the hormone regulating red-cell
production, exhibits a similar inhibition of granulocyte development. The rela-
tionship between these cells and the lymphoid series is less clear, but evidence
points to transformation of lymphoid-like cells residing in the bone marrow into
the myeloid lineage (Rosse and Yoffey, 1967; Yoffey, 1960).
The prevalent view is that erythrocytes and granulocytes come from a common
stem cell, but follow different pathways toward differentiation. Lymphocytes
may come from a different stem cell, but can transform into the granulocytic ma-
turation sequence under certain conditions. The study of the kinetics of granu-
locyte formation would suggest that transformation is not the major source of
granulocytic precursors and functions only when the demand for granulocytes is
high. Post-natal lymphopoiesis is felt to be a result of the migration of some
ancestor in the developing fetal bone-marrow to the thymus and other lymphoid
structures (Wintrobe, 1969, p. 16). This would imply a common ancestor for all
the blood cells and illustrates the still-existing confusion. This monophyletic
concept does not appreciably alter our understanding of the process of prolifera-
tion and differentiation of granulocytes from some stem cell, regardless of its
ultimate origin.
THE MYELOPOIETIC STEM CELL
The search for an identifiable stem cell has been one of the most fruitless but
yet most important subjects in the study of hemopoiesis. As indicated above,
the conclusive demonstration of the complete developmental lineage of a granu-
locyte without knowing the starting point is virtually impossible.
Several approaches to the problem have been attempted (fig. 3). Till and
McCulloch's (1961) previously described studies of hemopoietic colony-formation
in the spleens of irradiated rats have indicated the existence of a pleuripotential
stem cell capable of giving rise to erythroid, myeloid, and lymphoid colonies.
These colonies have been shown to arise from a single cell (Becker, et al., 1963).
When mast cells or normal bone-marrow cells are cultured in tissue-culture
medium partially solidified with agar, certain of the cells have the ability to form
discrete colonies on the agar surface by repeated cell division (Pluznik and Sachs,
1965; Bradley and Metcalf, 1966). The colonies produced in this manner are
primarily granulocytic, and in early work it was suggested that the colony-forming
units (CFU) were analogous to the stem cells forming colonies in the spleen (Pluznik
and Sachs, 1965; Bradley and Metcalf, 1966).
The suggestion that the in vitro colony-forming cells are more differentiated
than the CFU's identified in the spleen-colony assay has been made by McCulloch
and Till (1970). The cells giving rise to in vitro colonies are primitive members
of the granulocytic series, not the transplantable CFU, but more likely a committed
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FIGURE 3. Various approaches to identification of the pleuripotential stem cell.
myeloid stem cell which has entered the differentiation cycle (Richard, et al.,
1970).
The question of whether either of these cells is the true primary stem cell in
intact animals still exists. It may be that those cells which are able to form
colonies in artificial essay systems are partially differentiated descendents of the
true pleuripotential stem cell that begins the hemopoietic pathway in intact animals.
MYELOPOIESIS AS A SERIES OF COMPARTMENTS
The sequence of identifiable cell types in the maturation of granulocytes begins
with a myeloblst form which possesses few of the morphologic characteristics of
mature segmented granulocytes. The sequence terminating in a mature neutro-
philic polymorphonuclear (PMN) leukocyte is illustrated in Figure 4.
Study of this sequence is facilitated if the process is divided into compartments
with finite limits which can be easily measured. Boggs (1965) set forth such a
compartmentalized scheme using the following divisions.
Stem Cell—primitive, highly undifferentiated (and unrecognizable) cells, which
give rise to mature granulocytes. These might further be subdivided into
committed and non-committed groups.
Mitotic—composed of cells which divide mitotically, corresponding to classical
myeloblasts, promyelocytes, and myelocytes.
Maturation—those cells consisting of cells corresponding to metamyelocytes
and ring, or stab, forms which have lost their capacity for mitotic division
but which continue differentiation into mature granulocytes.
Storage—the bone-marrow reserve of segmented mature granulocytes (fig. 4).
KINETICS AND CONTROL
From a description of the pathways of granulocytic differentiation, it is useful
to turn to the kinetics of the process of granulopoiesis. The process of differentia-
tion from the stem-cell compartment is accompanied by proliferation through the
myelocyte stage, but the maturation process progresses alone past this point
(King-Smith and Morley, 1970). The transit time from stem cell to metamyelocyte
Stem C e l l
Mormal Rat
Lethal X-Ray
Stem C e l l
Stem Cells Normal—Rat
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The compartmental scheme of granulopoiesis showing the cell types in each com-
partment and four levels where control factors might act.
(the proliferation compartment) is in the vicinity of 140 hours under normal
conditions (Cronkite and Vincent, 1970). The minimum time needed to traverse
the maturation compartment and the bone-marrow granulocyte reserve is 96
hours, with a maximum of 144 hours (Cronkite and Vincent, 1970). This estab-
lishes an obligatory bone-marrow transit-time on the order of 10 days, with an
average of two and a half additional days spent in the marrow-reserve compart-
ment (King-Smith and Morley, 1970). Movement of granulocytes through the
maturation compartment is believed to be a "first-in, first-out" process (Maloney
and Patt, 1968). Additionally, King-Smith and Morley (1970) estimate the
marrow reserve as six times the total blood granulocyte pool, if it contains all of
the mature granulcytes and the most nearly mature band forms.
The above information is derived from experimental measurements and from
computer simulation of the process of granulopoiesis. This knowledge of cell
kinetics has proved to be the key to predicting and to proving experimentally
the existence of feedback-type control-mechanisms. Computer simulation of
granulopoiesis has shown the probability that three feedback loops exist, each of
which would regulate a particular phase of the entire process (King-Smith and
Morley, 1970). These feedback loops may come directly from a sensor for the
Stem
Cell
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number of a particular kind of granulocyte in the peripheral blood, or from the
destruction of phagocytic cells in extra-vascular tissue. A more sophisticated
feedback system might be postulated that would involve the neuro-endocrine axis
with production of a specific hormone perhaps similar to erythropoietin (fig. 5).
Little evidence exists for acceptance or rejection of any of these hypotheses.
It has also been possible to demonstrate three categories of stimulating factor
acting on granulopoiesis. First, the leukocytosis-inducing factor (LIF) has been
shown to promote release of cells from the marrow storage pool (Dornfest, et al.,
1962; Boggs, et al., 1966; Katz, et al., 1966). Secondly, a serum-protein factor
stimulating proliferation of granulocytic precursors (Colony-Stimulating Factor,
CSF) was demonstrated in vitro by Metcalf's group (Bradley and Metcalf, 1966;
Stanley and Metcalf, 1969) and in vivo by our laboratory (Graham, Morrison and
Toepfer, 1968; Graham and Morrison/ 1970; Graham and McMahon, 1971).
Bone
Marrow
Blood
Vessel
Tissue
(Connective)
NEURO-ENDOCRINE
SYSTEM
FIGURE 5. Possible feedback loops controlling stages in the development of granulocytes.
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Finally, our laboratory has demonstrated the existence of a rat-serum macro-
globulin which stimulates differentiation without significantly affecting the rate of
proliferation (Graham, et al., In prep.).
It should also be mentioned that a lesser known, but potentially more exciting
system of inhibitory factors exists. The granulocytic chalone was discovered by
Rhyomaa and his coworkers several years ago (Rytomaa and Kivinieme, 1968b).
Metcalf has reported inhibition of colony-stimulating factor by a lipoprotein in
the macroglobulin fraction of serum (Donald Metcalf, personal communication,
1971). Our laboratory has been working with a protein in the 120,000-800,000-
dalton range which inhibits granulocytic development in vivo and repopulation
of myelo-depleted bone marrow. The known properties of these factors are sum-
marized in Table 1.
Thus, at the present time we have considerable knowledge of the granulopoietic
pathway, its timing, and the control factors which regulate it. With this infor-
mation it is possible to begin the study of abnormal granulopoeisis, such as myelo-
genous leukemia.
TABLE 1
Substances implicated in the control of granulopoiesis as of July 1972
and their known characteristics
I. Colony Stimulating Factor (Myelopoietic Factor)—60,000 daltons, alphai globulin, glyco-
protein, stimulates proliferator.
II. Macroglobulin—"alpha" macroglobulin; 800,000-1,200,000 daltons, glycoprotein, little
effect on division in vivo; stimulates differentiation.
III. Release Factors—reports of chemical nature varied, causes release of mature cells from
marrow in response to stress.
IV. Chalone—small non-protein; 4,000-12,000 daltons, inhibits mitosis.
V. Antichalone—protein; 30,000-60,000 daltons; inhibits chalone effect.
VI. CSF Inhibitor—lipoprotein in macroglobulin fraction, inhibits colony stimulating factor.
VII. Inhibitor "X"—intermediate-size protein; 120,000-800,000 daltons, inhibits granulocytic
development in vivo; and repopulation of marrow in myelo-depleted rats.
ALTERED CONTROL MECHANISMS IN MYELOGENOUS LEUKEMIA
In the introduction to this paper, the reasons for stressing the investigation
of the mechanism controlling the development of granulocytes and its role in the
production of the leukemic state were discussed. The transmission of most
leukemia viruses from parent to offspring in a "vertical" type of infection, and the
probability of resulting development of specific immunologic tolerance of the
foreign viral antigens, mean that conventional vaccination is unlikely to be effective.
Also, Metcalf (1971) has succinctly pointed out that leukemic cells may not be
autonomous cancer cells and that the disease process in some types of leukemia
may be reversible (fig. 1). He suggests that the virus may affect production of
control factors rather than permanently alter the cells.
An attempt has been made in our laboratory to analyze this hypothesis, using
murine myelogenous leukemia as a model system. The C57B1/6J inbred mouse
strain is susceptible to the C1498 transplantable myelogenous leukemia, although
it has a very low incidence of spontaneous leukemia. The C1498 tumor may be
maintained in the C57bl/6J mouse strain by implantation of a suspension of the
tumor cells subcutaneously into the axillary region of the recipient mouse. Fol-
lowing a latent period of three to six days, a tumor develops at the site of implan-
tation, along with a frank leukemia in the blood and blood-forming (bone marrow,
spleen, etc.) organs of the mouse. The tumor is transplantable with 100 percent
success and results in death of the recipient in an average 13.9 days established in
over 200 trials in our laboratory. It should be noted that murine myelogenous
leukemis is an acute form of the disease in which the first hematologic symptoms
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appear on the fifth day post-implantation and few, if any, remissions occur before
death follows, during the 10th through 16 days. A detailed study of this leukemia
has been completed and is in the process of publication (McMahon and Graham,
In prep.).
A test group of 20 mice was used in each experiment, along with suitable con-
trol groups sham injected with saline or with bovine albumin. The control sub-
stances and antisera evaluated were given in a quantity previously demonstrated
to produce statistically significant changes in the bone-marrow cytology of normal
albino rats. (Graham, Earney, McMahon, and Tjan, 1972; Graham, McMahon,
Earney, and Tjan, In press). For the factors, this was 40 mg per kg body weight.
Two basic approaches have been attempted to learn whether the production
of granulopoietic control factors is defective in murine myelogenous leukemia or
whether the leukemic cell is insensitive to the normal control substances. First,
TABLE 2
Summary of data from preliminary experiments testing effects of granulopoietic-control
substances on murine myelogenous leukemia
TWELVE DAYS
Post-Tumor Implantation
Survival (days)
Leukemia
Leukemia+BSA
Leukemia-|-MF
Leukemia+AMF (A)
Leukemia+SHAM
Leukemia+"X"
Leukemia+MG
Leukemia+AMF(B)
Leukemia+AMG
13
13
14.
14
.9
.4
.3
.6
15.5
16.
16.
18.
18.
.3
.3
,7
.8
Leukocyte (X10
Leukemia
Leukemia+AMF(A)
Leukemia+ " X "
Leukemia+SHAM
Leukemia+MF
Leukemia -j-AMG
Leukemia+MG
Leukemia+AMF(B)
Leukemia 4- B S A
3)
7
8
6
5
4
4
3
3
3
.27
.62
.37
.42
.89
.63
.82
.73
.36
Hematocrit (%)
Leukemia
Leukemia+MF
Leukemia+AMF (A)
Leukemia+SHAM
Leukemia+B S A
Leukemia+MG
Leukemia+AMF (B)
Leukemia+"X "
Leukemia 4- AMG
33
37
38
41
42
43
44
45
50
.9
.3
.3
.9
.8
.6
.3
.8
.0
EIGHTEEN DAYS
Post-Tumor Implantation
Red Blood Cell (X10(
Leukemia+AMF (B)
Leukemia+B S A
Leukemia -j-MG
Leukemia+AMF (A)
Leukemia+SHAM
Leukemia+AMG
Leukemia+MF
Leukemia
Leukemia+"X"
!)
3
3
4
4
4
4
4
4
5
.12
.45
.08
.08
.23
.37
.56
.87
.72
Leukocyte (X103)
Leukemia+AMF(B)
Leukemia+AMG
Leukemia
Leukemia+MG
Leukemia+"X"
Leukemia+AMF(A)
Leukemia+B S A
Leukemia+SHAM
Leukemia+MF
3.
5.
5.
5.
6.
6.
7.
7.
8.
80
17
18
18
63
25
45
72
85
Hematocrit (%)
Leukemia+AMG
Leukemia+"X ! I
Leukemia+MF
Leukemia+SHAM
Leukemia
Leukemia+AMF(A)
Leukemia+B S A
Leukemia+MG
Leukemia+AMF (B)
39
38
34
33
32
30
29
29
26
.7
.3
.5
.8
.1
.0
.8
.0
.0
a treatment regimen was established, beginning with the first appearance of
leukemic symptoms. The different control factors were injected every other day.
Later, injections were increased to a daily schedule, with double the dosage of
factor.
Secondly, an effort was made to protect mice against the leukemia by admin-
istering the control factors before injection of tumor cells. Preliminary experi-
ments revealed that prophylactic administration of the control substances produced
no change in the disease course, except for a prolonged survival of mice injected
with the low-molecular-weight myelopoietic-factor (CSF).
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In assaying the effects of injections of stimulatory or inhibitory factors, sur-
vival time and peripheral leukocyte, erythrocye, and hematocrit values were
initially followed. We have since added the parameters of organ and tumor
pathology and of bone-marrow cytology in order to have the most sensitive mea-
sure of the effect of a control-factor injection on the disease course.
Early studies (Table 2) have demonstrated that antiserum to the low-molecular-
weight myelopoietic-factor is effective in extending the survival of mice implanted
with the C1498 tumor if administered prior to tumor implantation. It has little
or no effect on the disease course if given after tumor injection. The antiserum
has little effect on hematologic values.
Alternate-day therapy with the macroglobulin factor (Table 2) effectively ex-
tends survival time and maintains the normal erythroid-leukocyte ratio in the
peripheral blood over the first 12 days post-tumor implantation. Anemia is pre-
vented during the same period and the animals remain "healthy" in appearance
and behavior.
Antiserum to the macroglobulin fraction injected on alternate days produced
similar results, with increased survival and delayed development of anemia and
elevated leukocyte counts (Table 2). The percentage of segmented granulocytes
in the peripheral blood was markedly lower in anti-macroglobulin-treated rats
than in untreated leukemia animals.
Similar studies of the effects of the inhibiting factor "X", being carried out at
the present time, suggest similar maintenance of normal hematologic values without
prolonged survival, but are incomplete. The pathologic and bone-marrow studies
are also in progress.
Anti-myelopoietic factor, given prophylactically, works in inhibiting the
normal myelopoietic factor and maintaining erythroid-myeloid balance, whereas
anti-myelopoietic factor therapy does not. This supports the hypothesis either
that leukemic animals no longer have a functional myelopoietic factor or that the
factor is altered in such a way as to be immunologically unrecognizable. Both
the macroglobulin factor and the antiserum to it affect the disease course, indi-
cating that this particular control factor is not substantially altered by the viral
genome inducing the disease process.
These results suggest that the leukemic state is due to an alteration in the
normal control mechanism and not to a permanent alteration of the cells. If
these findings are born out in further studies, myelogenous leukemia stands in
direct contrast to most forms of neoplasia, where cells are permanently transformed.
Other laboratories have already suggested that this is the case for human myelo-
genous leukemia. These preliminary results serve not only to suggest a new direc-
tion for cancer research, but also to illustrate the need for understanding develop-
ment processes. Further studies will indicate the significance of control-factor
alterations in the mechanism of myelogenous leukemia.
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